Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
2.
J. bras. pneumol ; J. bras. pneumol;43(3): 195-201, May-June 2017. tab
Artículo en Inglés | LILACS | ID: biblio-893834

RESUMEN

ABSTRACT Objective: To use baseline audiogram parameters in order to ascertain whether drug-resistant tuberculosis (DR-TB) has effects on hearing, as well as to describe the configurations of the audiograms and to determine whether there are parameters that can be associated with those configurations. Methods: This was a prospective study involving patients diagnosed with DR-TB at a tuberculosis treatment center in the state of Ogun, in Nigeria. The patients included in the study were submitted to pure tone audiometry at baseline (within two weeks after treatment initiation). For comparative analyses, data regarding demographic and clinical characteristics were collected from the medical records of the patients. Results: The final sample comprised 132 patients. The mean age of the patients was 34.5 ± 12.6 years (range, 8-82 years), and the male:female ratio was 2:1. Of the 132 patients, 103 (78.0%) resided in neighboring states, 125 (94.7%) had previously experienced antituberculosis treatment failure, and 18 (13.6%) were retroviral-positive. Normal audiograms were found in 12 patients (9.1%), whereas sensorineural hearing loss was identified in 104 (78.8%), the two most common configurations being ascending, in 54 (40.9%), and sloping, in 26 (19.7%). Pure-tone averages at low frequencies (0.25-1.0 kHz) and high frequencies (2.0-8.0 kHz) were 33.0 dB and 40.0 dB, respectively. Regarding the degree of hearing loss in the better ear, 36 patients (27.3%) were classified as having normal hearing and 67 (50.8%) were classified as having mild hearing loss (26-40 dB), whereas 29 (21.9%) showed moderate or severe hearing loss. Among the variables studied (age, gender, retroviral status, previous treatment outcome, and weight at admission), only male gender was associated with audiometric configurations. Conclusions: In this sample of patients with DR-TB, most presented with bilateral, mild, suboptimal sensorineural hearing loss, and ascending/sloping audiometric configurations were associated with male gender.


RESUMO Objetivo: Utilizar parâmetros do audiograma basal para verificar se a tuberculose resistente (TB-R) tem efeitos na audição, descrever as configurações dos audiogramas e determinar se há parâmetros que possam ser associados a essas configurações. Métodos: Estudo prospectivo com pacientes diagnosticados com TB-R em um centro de tratamento de tuberculose no estado de Ogun, Nigéria. Os pacientes incluídos no estudo foram submetidos à audiometria de tons puros em até duas semanas após o início do tratamento (audiometria basal). Características demográficas e clínicas foram coletadas dos prontuários médicos dos pacientes para análises comparativas. Resultados: A amostra final envolveu 132 pacientes. A média de idade dos pacientes foi de 34,5 ± 12,6 anos (variação, 8-82 anos), e a razão homem:mulher foi de 2:1. A maioria dos pacientes (n = 103; 78,0%) residia nos estados vizinhos e tinha história de falha de tratamento antituberculose (n = 125; 94.7%); 18 (13.6%) apresentavam status retroviral positivo. Doze pacientes (9,1%) apresentaram audiogramas normais, e 104 (78,8%) apresentaram perda auditiva neurossensorial, sendo as configurações mais comuns do tipo ascendente, em 54 (40,9%), e descendente, em 26 (19,7%). As médias de tons puros em frequências baixas (0,25-1,0 kHz) e altas (2,0-8,0 kHz) foram de 33,0 dB e 40,0 dB, respectivamente. Quanto ao grau de perda auditiva no melhor ouvido, 36 pacientes (27,3%) apresentaram audição normal, e 67 (50,8%) apresentaram perda auditiva leve (26-40 dB), enquanto 29 (21,9%) mostraram perda auditiva moderada ou grave. Entre as variáveis estudadas (idade, gênero, status retroviral, desfecho de tratamento anterior e peso na admissão), somente o gênero masculino foi associado às configurações audiométricas. Conclusões: Nesta amostra de pacientes com TB-R, a maioria apresentou perda auditiva neurossensorial leve e subótima bilateralmente, com configurações audiométricas ascendentes/descendentes associadas ao gênero masculino.


Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Adulto Joven , Antibióticos Antituberculosos/efectos adversos , Umbral Auditivo/efectos de los fármacos , Umbral Auditivo/fisiología , Pérdida Auditiva/inducido químicamente , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Resistente a Múltiples Medicamentos/fisiopatología , Audiometría de Tonos Puros/métodos , Pérdida Auditiva/fisiopatología , Estudios Prospectivos , Valores de Referencia , Índice de Severidad de la Enfermedad , Factores Sexuales , Factores de Tiempo , Insuficiencia del Tratamiento , Tuberculosis Resistente a Múltiples Medicamentos/complicaciones
3.
Gut and Liver ; : 250-254, 2016.
Artículo en Inglés | WPRIM | ID: wpr-193421

RESUMEN

BACKGROUND/AIMS: To determine the incidence and clinical characteristics of tuberculosis (TB) medication-associated Clostridium difficile infection. METHODS: This multicenter study included patients from eight tertiary hospitals enrolled from 2008 to 2013. A retrospective analysis was conducted to identify the clinical features of C. difficile infection in patients who received TB medication. RESULTS: C. difficile infection developed in 54 of the 19,080 patients prescribed TB medication, representing a total incidence of infection of 2.83 cases per 1,000 adults. Fifty-one of the 54 patients (94.4%) were treated with rifampin. The patients were usually treated with oral metronidazole, which produced improvement in 47 of the 54 patients (87%). Twenty-three patients clinically improved with continuous rifampin therapy for C. difficile infection. There were no significant differences in improvement between patients treated continuously (n=21) and patients in whom treatment was discontinued (n=26). CONCLUSIONS: The incidence of C. difficile infection after TB medication was not low considering the relatively low TB medication dosage compared to other antibiotics. It may not be always necessary to discontinue TB medication. Instead, decisions concerning discontinuation of TB medication should be based on TB status.


Asunto(s)
Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antiinfecciosos/uso terapéutico , Antibióticos Antituberculosos/efectos adversos , Clostridioides difficile , Enterocolitis Seudomembranosa/inducido químicamente , Incidencia , Metronidazol/uso terapéutico , Estudios Retrospectivos , Rifampin/efectos adversos , Resultado del Tratamiento , Tuberculosis/tratamiento farmacológico
4.
Yonsei med. j ; Yonsei med. j;: 582-585, 2015.
Artículo en Inglés | WPRIM | ID: wpr-38890

RESUMEN

There are several reports to demonstrate that rifampicin, a major anti-tuberculosis agent, is associated with some adverse renal effects, with a few cases of rifampicin-induced minimal change disease (MCD). In the present case, a 68-year-old female presented with nausea, vomiting, foamy urine, general weakness and edema. She had been taking rifampicin for 4 weeks due to pleural tuberculosis. The patient had no proteinuria before the anti-tuberculosis agents were started, but urine tests upon admission showed heavy proteinuria with a 24-h urinary protein of 9.2 g/day, and serum creatinine, albumin, and total cholesterol levels were 1.36 mg/dL, 2.40 g/dL, and 283 mg/dL, respectively. MCD was diagnosed, and the patient achieved complete remission after cessation of rifampicin without undergoing steroid therapy.


Asunto(s)
Anciano , Femenino , Humanos , Antibióticos Antituberculosos/efectos adversos , Edema/etiología , Pruebas de Función Renal , Glomérulos Renales/patología , Náusea/etiología , Nefrosis Lipoidea/inducido químicamente , Proteinuria , Inducción de Remisión , Rifampin/efectos adversos , Resultado del Tratamiento , Tuberculosis Pleural/tratamiento farmacológico
7.
Artículo en Coreano | WPRIM | ID: wpr-17493

RESUMEN

Pseudomembranous colitis (PMC) is known to be associated with the administration of antibiotics which alter normal gastrointestinal flora and allow overgrowth of Clostridium difficile. Most cases of rifampicin-induced PMC are seen in patients with pulmonary tuberculosis, but not with gastrointestinal tuberculosis. We report a case of PMC associated with rifampicin therapy in a patient with gastrointestinal tuberculosis. A 65-year-old female patient with rectal cancer and gastrointestinal tuberculosis was admitted due to abdominal pain and diarrhea. She was treated with anti-tuberculosis agents containing rifampicin. On colonoscopic examination, mucoid exudates and yellowish plaque lesions were observed. Anti-tuberculosis agents were stopped, and the patient was treated with metronidazole. Symptoms were relieved and did not recur when all the anti-tuberculosis agents except rifampicin were started again. When a patient complains of abdominal pain or diarrhea while taking rifampicin, the physician should consider the possibility of rifampicin-associated PMC.


Asunto(s)
Anciano , Femenino , Humanos , Antibióticos Antituberculosos/efectos adversos , Enterocolitis Seudomembranosa/diagnóstico , Neoplasias del Recto/complicaciones , Rifampin/efectos adversos , Sigmoidoscopía , Tuberculosis Gastrointestinal/complicaciones
8.
J Biosci ; 2008 Nov; 33(4): 527-37
Artículo en Inglés | IMSEAR | ID: sea-110625

RESUMEN

The global impact of the converging dual epidemics of tuberculosis (TB) and human immunodeficiency virus (HIV) is one of the major public health challenges of our time. The World Health Organization (WHO) reports 9.2 million new cases of TB in 2006 of whom 7.7% were HIV-infected. Tuberculosis is the most common opportunistic infection in HIV-infected patients as well as the leading cause of death. Further,there has been an increase in rates of drug resistant tuberculosis, including multi-drug (MDRTB) and extensively drug resistant TB (XDRTB), which are difficult to treat and contribute to increased mortality. The diagnosis of TB is based on sputum smear microscopy, a 100-year old technique and chest radiography,which has problems of specificity. Extra-pulmonary, disseminated and sputum smear negative manifestations are more common in patients with advanced immunosuppression. Newer diagnostic tests are urgently required that are not only sensitive and specific but easy to use in remote and resourc-poor settings. Treatment of HIV-TB co-infection is complex and associated with high pill burden, overlapping drug toxicities,risk of immune reconstitution inflammatory syndrome (IRIS) and challenges related to adherence. From a programmatic point of view, screening of all HIV-infected persons for tuberculosis and vice-versa will help identify co-infected patients who require treatment for both infections. This requires good coordination and communication between the TB and AIDS control programs, in India.


Asunto(s)
Fármacos Anti-VIH/efectos adversos , Antibióticos Antituberculosos/efectos adversos , Brotes de Enfermedades/prevención & control , Interacciones Farmacológicas , Farmacorresistencia Bacteriana Múltiple , Infecciones por VIH/complicaciones , Humanos , Incidencia , India/epidemiología , Tamizaje Masivo , Prevalencia , Tuberculosis/complicaciones
9.
J. bras. pneumol ; J. bras. pneumol;33(6): 691-698, nov.-dez. 2007. tab
Artículo en Inglés, Portugués | LILACS | ID: lil-471292

RESUMEN

OBJETIVOS: Descrever os aspectos clínicos e terapêuticos da tuberculose pulmonar e comparar os efeitos adversos e resultados do tratamento entre idosos e não idosos. MÉTODOS: Foi realizado um estudo caso-controle com 117 indivíduos idosos (acima de 60 anos) e 464 não idosos (15-49 anos) portadores de tuberculose pulmonar atendidos no Instituto de Doenças do Tórax da Universidade Federal do Rio de Janeiro no período de 1980 a 1996. RESULTADOS: No grupo de idosos, houve associação entre diabetes mellitus (OR = 3,98; IC95 por cento = 2,07-7,65; p = 0,001), doenças pulmonares (OR = 7,24; IC95 por cento = 3,64-14,46; p = 0,001) e cardiovasculares (OR = 5,86; IC95 por cento = 2.88-11.95; p = 0,001). O tabagismo (OR = 2,07; IC95 por cento = 1,26-3,42; p = 0,002) e o etilismo (OR = 1,63; IC95 por cento = 1,01-2,68; p = 0,041) também foram mais freqüentes neste grupo. O tratamento levou a freqüentes reações adversas nos idosos (OR = 1,62; IC95 por cento = 1,04-2,54; p = 0,024), principalmente de origem gastrintestinal (OR = 1,64; IC95 por cento = 1,01-2,77; p = 0,047), e sua eficácia foi menor neste grupo: apenas 51 por cento de cura e 24 por cento de óbitos. O abandono do tratamento foi elevado nos dois grupos, em torno de 23 por cento. CONCLUSÕES: As reações adversas e o resultado do tratamento foram piores nos idosos, com maior freqüência de complicações e letalidade, devido a uma maior toxicidade farmacológica e a uma maior prevalência de doenças associadas neste grupo etário.


OBJECTIVE: To describe the clinical and therapeutic aspects of pulmonary tuberculosis and compare the adverse effects of the treatment and its outcome in elderly and nonelderly patients. METHODS: This was a case-control study of 117 elderly individuals (over the age of 60 years) and 464 nonelderly individuals (aged 15-49 years). All subjects presented pulmonary tuberculosis that had been diagnosed and treated at the Thoracic Diseases Institute of the Federal University of Rio de Janeiro between 1980 and 1996. RESULTS: In the elderly group, pulmonary tuberculosis was found to be correlated with diabetes (OR = 3.98; 95 percent CI = 2.07-7.65; p = 0.001), lung disease (OR = 7.24; 95 percent CI = 3.64-14.46; p = 0.001) and heart disease (OR = 5.86; 95 percent CI = 2.88-11.95; p = 0.001). Smoking (OR = 2.07; 95 percent CI = 1.26-3.42; p = 0.002) and alcohol abuse (OR = 1.63; 95 percent CI = 1.01-2.68; p = 0.041) were also more common in the elderly group. In the elderly group, the treatment more frequently resulted in adverse reactions (OR = 1.62; 95 percent CI = 1.04-2.54; p = 0.024), especially gastrointestinal reactions (OR = 1.64; 95 percent CI = 1.01-2.77; p = 0.047), and treatment efficacy was lower: cure rate, 51 percent; mortality rate, 24 percent. Treatment adherence was low (approximately 77 percent) in both groups. CONCLUSIONS: In the elderly group, adverse reactions were more common, treatment outcomes were less favorable, there was a greater frequency of clinical complications and deaths related to drug toxicity, and the prevalence of concomitant diseases was higher.


Asunto(s)
Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antibióticos Antituberculosos/efectos adversos , Antituberculosos/efectos adversos , Tuberculosis Pulmonar/tratamiento farmacológico , Antibióticos Antituberculosos/uso terapéutico , Antituberculosos/uso terapéutico , Brasil/epidemiología , Métodos Epidemiológicos , Hospitales Universitarios , Isoniazida/efectos adversos , Isoniazida/uso terapéutico , Cooperación del Paciente/estadística & datos numéricos , Pirazinamida/efectos adversos , Pirazinamida/uso terapéutico , Rifampin/efectos adversos , Rifampin/uso terapéutico , Fumar/epidemiología , Resultado del Tratamiento , Tuberculosis Pulmonar/epidemiología , Tuberculosis Pulmonar/mortalidad
10.
Artículo en Inglés | IMSEAR | ID: sea-110569

RESUMEN

Thrombocytopenia is an uncommon but potentially life threatening complication of certain anti-tubercular drugs and is characterized by rapid destruction of platelets whenever an offending drug is taken by a susceptible person. Here is a case report of Rifampicin induced Thrombocytopenia. This case is being reported for purpose of its rare occurrence and documentation.


Asunto(s)
Adulto , Antibióticos Antituberculosos/efectos adversos , Femenino , Humanos , Púrpura/etiología , Rifampin/efectos adversos , Trombocitopenia/inducido químicamente , Tuberculosis Pulmonar/tratamiento farmacológico
11.
Artículo en Inglés | IMSEAR | ID: sea-85813

RESUMEN

Rifampicin is a crucial component of treatment regimens for tuberculosis and has been in use since the early 1970's. It is usually considered safe. Rarely life-threatening complications like acute renal failure or acute thrombocytopaenia may manifest during treatment with rifampicin. In our experience at the Tuberculosis Research Centre of treating more than 8000 pulmonary and extrapulmonary tuberculosis patients with rifampicin-containing regimens over the last 30 years, we are reporting 3 cases of probably rifampicin-induced acute renal failure. Despite extreme therapeutic safety of this drug the clinician must be aware of this rare complication, which if detected early is completely reversible.


Asunto(s)
Adolescente , Adulto , Antibióticos Antituberculosos/efectos adversos , Humanos , Lesión Renal Aguda/inducido químicamente , Masculino , Rifampin/efectos adversos , Tuberculosis Pulmonar/tratamiento farmacológico
12.
J Indian Med Assoc ; 2004 Jan; 102(1): 20, 22-5
Artículo en Inglés | IMSEAR | ID: sea-106043

RESUMEN

Rifampicin re-administration may cause immunologically mediated acute tubulo-interstitial injury. Retrospectively, 170 consecutive cases with acute renal failure (ARF) following re-treatment with rifampicin (71% males, 29% females, age 21 to 68 years) were analysed, which accounted for 12% of all ARF patients treated by two large dialysis referral centres in Romania, Timisoara and Iasi, between 1974-2001 and 1988-2001, respectively. The most frequent clinical features of rifampicin-induced ARF were: Anuria, gastro-intestinal (abdominal pain, nausea, vomiting and diarrhoea) and "flu-like" symptoms. Urine analysis revealed sterile leucocyturia in 54%, proteinuria in 31%, haematuria in 26% and haemoglobinuria in 7% of cases. Haemolytic anaemia was frequent, found in 66% of the patients; half of these had Hct values of < 30%, thrombocytopenia and also more severe renal damage (a longer anuric phase and a slower recovery of the renal function), thus suggesting a severe multi-target autoimmune aggression. The association of hepatic injury--not explained by prior hepatic disease, B or C hepatitis virus infection or history of alcohol abuse--was encountered in 17% of the cases, without a significant influence on the renal and the general outcome. The outcome of rifampicin-induced ARF is generally favourable, with complete recovery of the renal function within 30 days in 52% of the cases and within 90 days in 92% of the cases. The mortality rate was 3.5%, compared to 21% for the overall ARF population treated during the same period (p < 0.05).


Asunto(s)
Adulto , Anciano , Anemia Hemolítica/epidemiología , Antibióticos Antituberculosos/efectos adversos , Femenino , Humanos , India/epidemiología , Lesión Renal Aguda/inducido químicamente , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Rifampin/efectos adversos
13.
Artículo en Coreano | WPRIM | ID: wpr-155620

RESUMEN

Pseudomembranous colitis is a dangerous but unusual side effect of antibiotics usage. We report a case of pseudomembranous colitis that developed in a 50-year-old female patient with diabetes mellitus during first line anti-tuberculous therapy including rifampicin. The patient was diagnosed with active pulmonary tuberculosis 70 days earlier. On admission, she suffered intermittent abdominal pain and watery diarrhea for 2 weeks. Colonoscopy revealed exudative, punctuate, raised plaques with skip areas or edematous hyperemic mucosa, and histopathologic findings were consistent with pseudomembranous colitis with typical volcano-like exudate. Symptoms improved on treatment with metronidazole. There was no recurrence after reinstitution of the anti-tuberculous agents excluding rifampicin. In patients with persistent diarrhea receiving anti-tuberculosis treatment, rifampicin associated pseudomembranous colitis should always be kept in mind.


Asunto(s)
Femenino , Humanos , Persona de Mediana Edad , Antibióticos Antituberculosos/efectos adversos , Resumen en Inglés , Enterocolitis Seudomembranosa/inducido químicamente , Rifampin/efectos adversos , Tuberculosis Pulmonar/tratamiento farmacológico
14.
Artículo en Inglés | WPRIM | ID: wpr-85299

RESUMEN

Pseudomembranous colitis is known to develop with long-term antibiotic administration, but antitubercular agents are rarely reported as a cause of this disease. We experienced a case of pseudomembranous colitis associated with rifampin. The patient was twice admitted to our hospital for the management of frequent bloody, mucoid, jelly-like diarrhea and lower abdominal pain that developed after antituberculosis therapy that included rifampin. Sigmoidoscopic appearance of the rectum and sigmoid colon and mucosal biopsy were compatible with pseudomembranous colitis. The antitubercular agents were discontinued and metronidazole was administered orally. The patient's symptoms were resolved within several days. The antituberculosis therapy was changed to isoniazid, ethambutol and pyrazinamide after a second bout of colitis. The patient had no further recurrence of diarrhea and abdominal pain. We report here on a case of pseudomembranous colitis associated with rifampin.


Asunto(s)
Anciano , Anciano de 80 o más Años , Humanos , Masculino , Antibióticos Antituberculosos/efectos adversos , Diarrea/etiología , Enterocolitis Seudomembranosa/inducido químicamente , Rifampin/efectos adversos , Tuberculosis Pulmonar/tratamiento farmacológico
15.
Rev. méd. hered ; 13(4): 148-152, dic. 2002. ilus
Artículo en Español | LILACS, LIPECS | ID: lil-339777

RESUMEN

We report the case of a patient with several adverse effects, of fatal consequence, associated with drugs used in the treatment for Tuberculosis. Patient was hospitalized at the Hospital Nacional Arzobispo Loayza of Lima, Peru, since May until July 2001. We identified the presence of several adverse effects associated with antituberculosis drugs (dermatitis, nausea, vomit, interstitial nephritis, hepatitis for drug and thrombocytopenia, associated with Intracraneal hemorrhage, of fatal consequence). This study reports a case very infrequent in the world (including Peru), in relation with the presence of several adverse effects of antituberculosis drugs, in the same patient, who died because of these effects. We want to inform the potential risks associated with antituberculosis drugs (of great use in Peru for the high prevalence of Tubersulosis), that must have a regimen and adequate control to avoid severe consequences.


Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Antibióticos Antituberculosos/efectos adversos , Antibióticos Antituberculosos/uso terapéutico
20.
Indian J Chest Dis Allied Sci ; 1995 Jan-Mar; 37(1): 35-8
Artículo en Inglés | IMSEAR | ID: sea-30137

RESUMEN

A 40-year-old male patient with chronic steroid dependent asthma developed pulmonary tuberculosis. After administration of antituberculosis therapy with rifampicin, isoniazid and pyrazinamide his asthma worsened. Omission of rifampicin from the drug regimen successfully controlled bronchospasm.


Asunto(s)
Adulto , Antibióticos Antituberculosos/efectos adversos , Asma/inducido químicamente , Progresión de la Enfermedad , Glucocorticoides/uso terapéutico , Humanos , Masculino , Rifampin/efectos adversos , Tuberculosis Pulmonar/complicaciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA